drugset / Trial / NCT03732625
Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study
Phase 4
Unknown
50 enrolled
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelOther
Summary
Open, multicenter, non randomized, single arm, pilot trial.
Timeline
- Start
- 2019-05
- Primary completion
- 2020-01
- Completion
- 2021-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Raltegravir | Other / unclassified | 1200 mg | — |